NICHOLAS MURPHY to Humans
This is a "connection" page, showing publications NICHOLAS MURPHY has written about Humans.
Connection Strength
0.124
-
Alterations in attentional processing in youth with misophonia: A phenotypical cross-comparison with anxiety patients. J Affect Disord. 2024 02 15; 347:429-436.
Score: 0.018
-
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacology. 2023 10; 48(11):1586-1593.
Score: 0.017
-
Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73.
Score: 0.016
-
A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-D-aspartate receptor blockade in healthy veterans. Neuropsychopharmacology. 2021 03; 46(4):820-827.
Score: 0.015
-
Anti-suicidal effects of IV ketamine in a real-world setting. Psychiatry Res. 2024 Jan; 331:115604.
Score: 0.004
-
Family Accommodation in Children and Adolescents With Misophonia. Behav Ther. 2024 May; 55(3):595-604.
Score: 0.004
-
Measuring misophonia in youth: A psychometric evaluation of child and parent measures. J Affect Disord. 2023 10 01; 338:180-186.
Score: 0.004
-
Noninvasive Brain Stimulation Techniques for Treatment-Resistant Depression: Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation. Psychiatr Clin North Am. 2023 06; 46(2):307-329.
Score: 0.004
-
Times Constraints, Lack of Confidence in Treatment, Stigma, and Confidentiality Concerns: Barriers to Care Among First-year Internal Medicine Residents During the COVID-19 Pandemic. J Psychiatr Pract. 2023 01 01; 29(1):11-14.
Score: 0.004
-
Biomarkers in Psychiatric Drug Development: From Precision Medicine to Novel Therapeutics. Adv Neurobiol. 2023; 30:287-297.
Score: 0.004
-
Clinical characteristics, impairment, and psychiatric morbidity in 102 youth with misophonia. J Affect Disord. 2023 03 01; 324:395-402.
Score: 0.004
-
Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2023 01 15; 321:140-146.
Score: 0.004
-
Effects of adding a diet intervention to exercise on hip osteoarthritis pain: protocol for the ECHO randomized controlled trial. BMC Musculoskelet Disord. 2022 Mar 05; 23(1):215.
Score: 0.004
-
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022 04; 47(5):1088-1095.
Score: 0.004
-
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
Score: 0.004
-
Distinct trajectories of antidepressant response to intravenous ketamine. J Affect Disord. 2021 05 01; 286:320-329.
Score: 0.004
-
Loss-of-function mutation in inositol monophosphatase 1 (IMPA1) results in abnormal synchrony in resting-state EEG. Orphanet J Rare Dis. 2019 01 07; 14(1):3.
Score: 0.003
-
Reduced occipital GABA in Parkinson disease with visual hallucinations. Neurology. 2018 08 14; 91(7):e675-e685.
Score: 0.003
-
Quantitative electroencephalography as a marker of cognitive fluctuations in dementia with Lewy bodies and an aid to differential diagnosis. Clin Neurophysiol. 2018 06; 129(6):1209-1220.
Score: 0.003